HELPNasdaqPharmaceutical PreparationsFiscal year ends March 31
Helus Pharma Inc.
Financials through fiscal 2026, year ended Mar 31, 2026Last filing: 40-F on Jun 29, 2026
$10.69+0.14 (+1.33%)
Close on Oct 19, 2026
Ownership
Who owns Helus Pharma's shares
Held by institutions
–
Shares held, 13F filers
Institutional holders
–
Net institutional buying
–
Insider trades, 12 months
8 buys · 0 sales
Net bought $9.63M
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Steven A. Cohen | 6,410,778 | 9.90% | 13G (passive) amendment | Sep 30, 2025 |
| VHCP Management III, LLC | 5,111,412 | 9.90% | 13G (passive) | Oct 31, 2025 |
| So Eric H. L. | 4,423,894 | 5.80% | 13D (active) | Sep 1, 2026 |
| Glavine Paul | 4,407,456 | 5.80% | 13D (active) | Sep 1, 2026 |
| Adage Capital Management, L.P. | 3,289,250 | 5.29% | 13G (passive) | Jun 30, 2026 |
| Deep Track Biotechnology Master Fund, Ltd. | 3,072,250 | 6.09% | 13G (passive) | Oct 28, 2025 |
| Israel A. Englander | 2,829,893 | 5.70% | 13G (passive) amendment | Apr 17, 2026 |
| Tang Capital Management, LLC | 1,830,097 | 9.10% | 13G (passive) amendment | Mar 31, 2025 |
| Point72 Asset Management, L.P. | 1,326,185 | 6.30% | 13G (passive) | May 20, 2025 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Eric H. L. So | Executive Chair, Director | 4,518,630 | 8.75% | Sep 11, 2026 |
| Michael Halstead | Chief Executive Officer | 168,568 | 0.33% | Sep 21, 2026 |
| Paul Glavine | Chief Growth Officer | 4,502,193 | 8.72% | Sep 11, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Michael Halstead Chief Executive Officer | Sep 21, 2026 | Buy | +100,000 | $13.47 | $1.35M | 168,568 |
| Eric H. L. So Executive Chair, Director | Sep 8, 2026 | Buy | +100,000 | $12.39 | $1.24M | 4,465,014 |
| Paul Glavine Chief Growth Officer | Sep 8, 2026 | Buy | +100,000 | $12.47 | $1.25M | 4,271,252 |
| Paul Glavine Chief Growth Officer | Sep 8, 2026 | Buy | +100,000 | $12.47 | $1.25M | 4,271,252 |
| Eric H. L. So Executive Chair, Director | Sep 4, 2026 | Buy | +100,000 | $12.09 | $1.21M | 4,365,014 |
| Paul Glavine Chief Growth Officer | Sep 3, 2026 | Buy | +100,000 | $11.78 | $1.18M | 4,171,252 |
| Eric H. L. So Executive Chair, Director | Sep 1, 2026 | Buy | +95,000 | $11.81 | $1.12M | 4,265,014 |
| Paul Glavine Chief Growth Officer | Aug 31, 2026 | Buy | +90,000 | $11.59 | $1.04M | 4,071,252 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.